Inka Saarinen
Inka Saarinen has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Juha Koskenvuo
Blueprint Genetics, 02150 Espoo, Finland
5 shared publications - Johanna Sistonen
Genome Unit, HUS Diagnostic Center Helsinki University Hospital Helsinki Finland
4 shared publications Kim Gall
4 shared publicationsTero-Pekka Alastalo
4 shared publications- Alicia Scocchia
Blueprint Genetics Inc, Seattle, USA
3 shared publications Lotta Koskinen
3 shared publications
Latest Publications
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 16
Genetic Findings from a Multigene Panel for Autoinflammatory Disease
- 23 May 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 16
Genetic Findings from a Multigene Panel for Autoinflammatory Disease
- Open Access
- 1 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0255933
Next-generation sequencing in childhood-onset epilepsies: Diagnostic yield and impact on neuronal ceroid lipofuscinosis type 2 (CLN2) disease diagnosis
Epilepsy is one of the most common childhood-onset neurological conditions with a genetic etiology. Genetic diagnosis provides potential for etiologically-based management and treatment. Existing research has focused on early-onset (<24 months) epilepsies; data regarding later-onset epilepsies is limited. The goal of this study was to determine the diagnostic yield of a clinically available epilepsy panel in a selected pediatric epilepsy cohort with epilepsy onset between 24–60 months of life and evaluate whether this approach decreases the age of diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2). Next-generation sequencing (NGS)-based epilepsy panels, including genes associated with epileptic encephalopathies and inborn errors of metabolism (IEMs) that present with epilepsy, were used. Copy-number variant (CNV) detection from NGS data was included. Variant interpretation was performed per American College of Medical Genetics and Genomics (ACMG) guidelines. Results are reported from 211 consecutive patients with the following inclusion criteria: 24–60 months of age at the time of enrollment, first unprovoked seizure at/after 24 months, and at least one additional finding such as EEG/MRI abnormalities, speech delay, or motor symptoms. Median age was 42 months at testing and 30 months at first seizure onset; the mean delay from first seizure to comprehensive genetic testing was 10.3 months. A genetic diagnosis was established in 43 patients (20.4%). CNVs were reported in 25.6% diagnosed patients; 27.3% of CNVs identified were intragenic. Within the diagnosed cohort, 11 (25.6%) patients were diagnosed with an IEM. The predominant molecular diagnosis was CLN2 (14% of diagnosed patients). For these patients, diagnosis was achieved 12–24 months earlier than reported by natural history of the disease. This study supports comprehensive genetic testing for patients whose first seizure occurs ≥ 24 months of age. It also supports early application of testing in this age group, as the identified diagnoses can have significant impact on patient management and outcome.
- 1 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0255933
Open AccessNext-generation sequencing in childhood-onset epilepsies: Diagnostic yield and impact on neuronal ceroid lipofuscinosis type 2 (CLN2) disease diagnosis
Epilepsy is one of the most common childhood-onset neurological conditions with a genetic etiology. Genetic diagnosis provides potential for etiologically-based management and treatment. Existing research has focused on early-onset (<24 months) epilepsies; data regarding later-onset epilepsies is limited. The goal of this study was to determine the diagnostic yield of a clinically available epilepsy panel in a selected pediatric epilepsy cohort with epilepsy onset between 24–60 months of life and evaluate whether this approach decreases the age of diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2). Next-generation sequencing (NGS)-based epilepsy panels, including genes associated with epileptic encephalopathies and inborn errors of metabolism (IEMs) that present with epilepsy, were used. Copy-number variant (CNV) detection from NGS data was included. Variant interpretation was performed per American College of Medical Genetics and Genomics (ACMG) guidelines. Results are reported from 211 consecutive patients with the following inclusion criteria: 24–60 months of age at the time of enrollment, first unprovoked seizure at/after 24 months, and at least one additional finding such as EEG/MRI abnormalities, speech delay, or motor symptoms. Median age was 42 months at testing and 30 months at first seizure onset; the mean delay from first seizure to comprehensive genetic testing was 10.3 months. A genetic diagnosis was established in 43 patients (20.4%). CNVs were reported in 25.6% diagnosed patients; 27.3% of CNVs identified were intragenic. Within the diagnosed cohort, 11 (25.6%) patients were diagnosed with an IEM. The predominant molecular diagnosis was CLN2 (14% of diagnosed patients). For these patients, diagnosis was achieved 12–24 months earlier than reported by natural history of the disease. This study supports comprehensive genetic testing for patients whose first seizure occurs ≥ 24 months of age. It also supports early application of testing in this age group, as the identified diagnoses can have significant impact on patient management and outcome.
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S233-S234
Retrospective review of genetic testing for inherited bone marrow failure syndromes
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S233-S234
Retrospective review of genetic testing for inherited bone marrow failure syndromes
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S220
Biallelic NRAP variants are a significant cause of dilated cardiomyopathy
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S220
Biallelic NRAP variants are a significant cause of dilated cardiomyopathy
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S221
Next-generation sequencing panels for hereditary hearing loss testing with approaches for difficult-to-sequence regions
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S221
Next-generation sequencing panels for hereditary hearing loss testing with approaches for difficult-to-sequence regions
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S221-S222
Diagnostic utility of next-generation sequencing panel tests in the diagnosis of skeletal dysplasias
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S221-S222
Diagnostic utility of next-generation sequencing panel tests in the diagnosis of skeletal dysplasias